Analyzing Revelation Biosciences (NASDAQ:REVB) and Vincerx Pharma (NASDAQ:VINC)

Revelation Biosciences (NASDAQ:REVB) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Profitability

This table compares Revelation Biosciences and Vincerx Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-84.25%	-51.31%
Vincerx Pharma	N/A	-187.73%	-126.26%

Analyst Recommendations

This is a summary of current recommendations and price targets for Revelation Biosciences and Vincerx Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	0	0	0	0	N/A
Vincerx Pharma	0	0	1	0	3.00

Vincerx Pharma has a consensus price target of $5.00, indicating a potential upside of 474.71%. Given Vincerx Pharma’s higher probable upside, analysts clearly believe Vincerx Pharma is more favorable than Revelation Biosciences.

Earnings & Valuation

This table compares Revelation Biosciences and Vincerx Pharma’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$120,000.00	$30.41	0.06
Vincerx Pharma	N/A	N/A	-$40.16 million	($1.89)	-0.46

Vincerx Pharma is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Revelation Biosciences has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.

Institutional and Insider Ownership

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 1.4% of Revelation Biosciences shares are held by company insiders. Comparatively, 20.6% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

About Revelation Biosciences

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.